TY - JOUR AU - Wedam, Suparna B. AU - Yang, Sherry X. PY - 2012 TI - Neoadjuvant bevacizumab and chemotherapy in breast cancer JF - Translational Cancer Research; Vol 1, No 1 (June 01, 2012): Translational Cancer Research Y2 - 2012 KW - N2 - Bevacizumab (Avastin, Roche-Genentech) is a humanized monoclonal antibody targeting all isoforms of the vascular endothelial growth factor A (VEGF-A), an important regulator of angiogenesis. It stimulates endothelial cell proliferation/migration as well as induces vascular leakage or vasodilatation, which are essential in a variety of physiological and pathological conditions (1). It has been found that VEGF-A expression is upregulated in various human tumors. Over the past decade, bevacizumab has been incorporated into chemotherapy for the treatment of cancer patients with advanced diseases including colorectal cancer, non-squamous non-small cell lung cancer, renal cell carcinoma and glioblastoma. UR - https://tcr.amegroups.org/article/view/375